In vivo tracking of tumor-specific T cells

Current Opinion in Immunology

Volumn 13, Issue 2, 2001, Pages 141-146

  Yee, Cassian ^a   Riddell, Stanley R ^a   Greenberg, Philip D ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; REVIEW;

ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE COUNT; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035314005     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00196-5     Document Type: Review

References (48)

1. T cell defined tumor antigens
2. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model
3. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens
4. The use of computer-assisted video image analysis for the quantification of CD8(+) T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
5. Flow cytometric measurement of intracellular cytokines
6. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
7. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
8. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
9. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
10. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
11. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
12. Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes
13. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
14. Phenotypic analysis of antigen-specific T lymphocytes
15. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients
16. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
17. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
18. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
19. CD8(+) T-cell selection, function, and death in the primary immune response in vivo
20. In situ detection of virus- and tumor-specific T-cell immunity
21. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype
22. + T cells during an acute virus infection
23. + T cells specific for EBV in healthy virus carriers
24. + T cells during the primary immune response to Epstein-Barr virus in vivo
25. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
26. A new look at T cells
27. Viral immune evasion due to persistence of activated T cells without effector function
28. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
29. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
30. Antigen-independent activation of naive and memory resting T cells by a cytokine combination
31. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
32. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
33. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
34. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
35. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
36. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
37. + cancers
38. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
39. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
40. Management of IL-2 toxicity
41. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo
42. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
43. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
44. + T cells
45. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
46. The central role of CD4(+) T cells in the antitumor immune response
47. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
48. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen